Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are between 65 and 79 years old and have been assessed as "unfit" or "frail" based on a standard health and fitness assessment, OR you are 80 years old or older (any fitness level)
• You have been diagnosed with a specific type of aggressive lymphoma (DLBCL, high-grade B-cell lymphoma, or a lymphoma that has transformed), confirmed by a tissue sample (biopsy)
• You have not previously received any systemic (whole-body) treatment for your lymphoma — a short course of low-dose steroids (prednisone up to 100 mg/day for up to 7 days) is allowed
• Your lymphoma is at an advanced or bulky stage (Stage 2 bulky, Stage 3, or Stage 4)
• Your heart is pumping well enough to receive a specific type of chemotherapy — confirmed by a heart scan showing at least 45% pumping function
• You have at least one measurable area of lymphoma visible on a CT or MRI scan
• You are well enough to carry out basic daily activities (as assessed by your doctor using a standard scale)
• Your blood counts, kidney function, and liver function meet minimum required levels (your doctor will check these with blood tests)
• You have tested negative for HIV, OR if HIV-positive, you are stable on treatment, your immune cell count is adequate, and the virus is undetectable in your blood
• You are willing and able to follow all study procedures, in your doctor's opinion
• Female patients must be past menopause or have had surgery that means they cannot become pregnant; male patients must agree to use reliable contraception or remain abstinent during treatment and for a specified period afterwards, and must not donate sperm during this time

Who may not be able to join:

• You have previously received systemic (whole-body) treatment for lymphoma (localised radiotherapy, steroids, and antibiotics are still allowed)
• You have previously had a solid organ transplant (such as a kidney, liver, or heart transplant)
• You have previously had a bone marrow or stem cell transplant from a donor
• Your lymphoma has spread to your brain or spinal cord (central nervous system)
• You have uncontrolled HIV, or an active hepatitis B or C infection (confirm with trial site if you have a history of hepatitis B or C)
• You have an active serious infection that is not under control
• You have had major surgery within the last 4 weeks before starting the trial (exceptions may be possible — confirm with trial site)
• You have significant heart disease, such as a heart attack in the last 3 months, severe heart failure, unstable heart rhythm, or unstable chest pain
• You have an autoimmune condition that is not well controlled
• You have a history of a serious brain condition called progressive multifocal leukoencephalopathy (PML)
• You have another serious illness or condition that your doctor believes could put you at risk or affect the study results
• You are unable to follow the study procedures, in your doctor's opinion
• You have a known allergy or serious reaction to any of the study drugs, or to similar types of antibody-based medicines
• You have received certain immune-based cancer treatments (including monoclonal antibodies for cancer) within the past 3 months
• You have taken part in another experimental cancer treatment trial within the last 28 days
• You have previously had radiotherapy to the chest area around your heart
• You are currently taking high-dose steroids (more than 50 mg/day of prednisone or equivalent) for reasons unrelated to your lymphoma symptoms (some lower-dose or inhaled steroid use may be permitted — confirm with trial site)
• You have or have had another cancer that could interfere with the trial, unless it was successfully treated and has been in remission without treatment for at least 2 years, or meets other specific exceptions (confirm with trial site)
• You have received a live vaccine (such as a live flu vaccine) within the 4 weeks before starting treatment, or expect to need one during the study

Important: Always verify eligibility with the trial site directly before applying.